Armoring cytokines to boost NK cell persistence, targeting NK cell receptors to improve efficacy of CAR-NK cells, engaging CAR-NK cell with NK cell engagers, targeting immunosuppressive tumor microenvironment to revitalize CAR-NK cells, supplying chemokine to improve CAR-NK cell infiltration, and reducing trogocytosis to prevent immune escape are the strategies used to overcome challenges of CAR-NK cell therapy. The gene discussed is KLRD1; the disease is neoplasm.